N-Zyme Lands $2.76 Million NIH Award for GERD Drug Trial
NEWARK, DE — N-Zyme Biomedical Inc. secured $2.76 million in federal research funding to advance fosamprenavir into a Phase II trial for patients whose gastroesophageal reflux disease persists despite proton …
N-Zyme Lands $2.76 Million NIH Award for GERD Drug Trial Read More